Business
Know the Business
Cigna is a $74B-equity, ~$98B-EV holding company that bolts the #1 US pharmacy benefit manager (Express Scripts, ~85% of revenue, ~3% pre-tax margin) onto a focused commercial-and-international medical insurer (Cigna Healthcare, ~17% of revenue, ~9% pre-tax margin). The market prices it at roughly 9x forward adjusted EPS, treating it as one consolidated managed-care name — but the two engines have entirely different economics, customer concentration, and regulatory exposures, and the equity story now hinges on whether the rebate-free PBM transition starting 2027 holds Express Scripts' margin without rupturing client retention. The biggest analytical mistake on this stock is conflating the PBM with insurer peers like ELV/HUM, or with utilization-spiked Medicare-heavy names like CVS/HUM/CNC.
Market Cap ($M)
FY2025 Revenue ($M)
FY2025 Adj. Op Income ($M)
Fwd Adj. P/E (x)
1. How This Business Actually Works
Cigna runs two completely different machines that share back-office, brand, and capital. Evernorth is a high-volume, low-take-rate distribution business — it adjudicates 2.22 billion adjusted Rx claims a year, dispenses high-cost specialty drugs through Accredo, and earns roughly 3 cents of pre-tax income per dollar of revenue. Cigna Healthcare is a mid-scale commercial insurer that collects premiums, assumes claim risk on ~21% of medical customers, and rents its network and admin capability to self-funded employers for the other ~79%, earning roughly 9 cents of pre-tax income per dollar of segment revenue.
The PBM is 5x bigger than the insurer by revenue and 1.7x larger by pre-tax income. The mental model that follows: Evernorth sets the size of the company; Cigna Healthcare sets its quality of earnings. Anyone who values the consolidated entity on a single multiple is averaging two unlike things.
Where each dollar comes from
Five mechanics produce essentially all of Cigna's pre-tax dollars. The first three are scale-driven; the last two are underwriting and float.
The single most important customer fact: one Evernorth pharmacy benefit client drove approximately 19% of total 2025 revenue from external customers (up from 16% in 2024). That is the multi-year Centene PBM contract, which began January 2024. A loss or sharp re-pricing of this single relationship would move group revenue by ~$50B and is the largest discrete operating risk in the model.
The capital-light tilt
Cash conversion is the cleanest cross-check. Cigna generated $9.6B of operating cash flow on $6.3B of net income in 2025 (1.5x). Claim reserves grow with revenue and capex is a rounding error. The 2024 net income dip to $3.4B was a non-cash VillageMD impairment, not a cash event.
2. The Playing Field
Two completely different competitive maps run inside this single ticker. On the insurance side, Cigna is the smallest of five large national managed-care companies and competes mostly with UnitedHealthcare and Anthem (Elevance) for large-employer commercial accounts. On the PBM side, Cigna's Express Scripts is #1 in a triopoly that processes roughly 80% of all US prescription claims. Read both maps, or you will misjudge the moat.
Peer scorecard
Three patterns come out of this table. First, net margins cluster at 1–3% — these are gross-dollar businesses, and looking at percent margin alone is misleading. Second, only UNH and ELV earned a clean year in 2025; CVS, HUM, and CNC were all impaired by Medicare/Medicaid utilization spikes or restructuring, with CNC posting an outright operating loss. Third, Cigna trades at the cheapest forward adjusted multiple of the clean operators — roughly 9x adjusted EPS versus ELV at ~14x and UNH at ~28x GAAP — partly because the PBM regulatory overhang is unresolved and partly because the Centene client concentration scares investors.
Where each peer competes hardest
The picture: UNH sits in the dominant top-right corner — bigger and more profitable than anyone. Cigna sits in the best position among the rest of the field on margin × growth, paired with the smallest multiple. ELV is its closest analog on commercial focus but lacks a Top-3 PBM. CVS and HUM are the visibly stressed names; Centene is the bottom-left outlier with negative margin.
Express Scripts' 2.22B adjusted claims figure is the only one Cigna publishes; the other Big-3 numbers are illustrative and consistent with industry estimates that the three together process ~80% of US equivalent claims. The point is structural — this is not a contestable market.
3. Is This Business Cyclical?
Yes, but the cycle is not GDP. The cycle that matters is the medical care ratio (MCR), which is the percentage of insurance premium that goes back out as claim payments. When utilization runs ahead of priced assumptions, MCR climbs and underwriting profit gets squeezed for 12–24 months until the next pricing cycle. Cigna's CH MCR has climbed from 81.3% in 2023 to 84.4% in 2025 — a textbook hard cycle.
Three forces drove the 2023–2025 run-up: post-COVID Medicare Advantage utilization catch-up (which Cigna escaped by selling MA to HCSC in March 2025), GLP-1 weight-loss drug spend that arrived as a brand-new $10–15K/patient line item, and Medicaid redeterminations that left a sicker remaining commercial pool. Cigna's cycle exposure is smaller than peers' because it is commercial-tilted (corporate utilization is more stable than senior utilization) and ASO-tilted (32% of segment revenue is fee, with no claim risk on the insurer balance sheet). But the 2025 MCR of 84.4% is still 310 basis points above 2023's 81.3%, and the IFP (individual exchange) business is the visible weak spot — Cigna has announced an ACA exit for plan year 2027.
Cigna's MCR is the lowest in the peer set. That is the structural payoff from being commercial-and-PBM rather than Medicare-and-Medicaid. The 2026 Q2/Q3 prints will show whether pricing actions catch the cost trend — that, more than any other single number, sets next year's earnings.
The PBM side has its own cycle, but it is a client cycle, not a utilization cycle. Big PBM contracts come up for renewal on 3-to-5-year terms, and a single loss can move group revenue dramatically. Cigna's recent renewals through end-of-decade with its three largest clients (Centene, Prime Therapeutics, Department of War / TRICARE) lengthen the next visible client-cliff to 2029–2030.
4. The Metrics That Actually Matter
Forget gross margin, P/B, and operating margin. In this business, five operating numbers explain almost all of value creation and failure. Watch them in this order.
The two yellow flags — MCR at 84.4% (Healthcare segment) and 19% single-client concentration (Evernorth) — are the two numbers that reset the equity story if they break. Everything else looks like a healthy, scaled, capital-light operation.
5. What Is This Business Worth?
This is one of the few healthcare names where sum-of-the-parts is genuinely the right lens, not a presentation crutch. Two reportable segments, with very different economics, very different competitive maps, very different multiples, and very different regulatory cycles. Consolidated multiples bury the difference.
The right way to think about it is to value Evernorth and Cigna Healthcare separately, capitalize the corporate cost drag at a group multiple, and net out debt.
The headline takeaway: at $282 the stock implies an enterprise value near the midpoint of a defensible SOTP range. It is neither obviously cheap nor obviously expensive on a static segment analysis. What makes it interesting is the option value on the rebate-free PBM transition: management has guided 2026 Evernorth adjusted operating income to a floor of $6.9B, below 2025's $7.2B, explicitly labeling it a transition cost. If the new model holds Evernorth pre-tax operating income above $7.0B in 2027 with retention intact, the PBM bucket re-rates higher and current valuation looks too low. If retention slips below 95% or the take-rate compresses faster than dispensary margin expands, Evernorth deserves a discount and the SOTP rolls back toward $65B EV.
The headline P/E is reported on different bases — UNH/ELV/HUM/CVS are GAAP TTM, while Cigna's 9.3x is on management-defined adjusted EPS — but the rank order is robust: Cigna trades at a discount to clean-earnings managed-care peers even though it has the lowest MCR and the strongest PBM franchise in the set. The discount is not crazy: it captures the rebate-free transition risk and the Centene concentration. It is also the asymmetry that keeps active investors interested.
The honest verdict on valuation: this stock is fair-to-slightly-cheap on a static SOTP. The interesting question is not the static value, but whether the next two events — 2026 MCR sequencing and 2027 rebate-free model launch — confirm or invalidate the discount. Skip the consolidated DCF. Track the two transitions.
6. What I'd Tell a Young Analyst
Don't value this as one company. It is two. The PBM trades closer to a logistics-and-services multiple (8-10x EBIT); the insurer closer to managed care (10-12x EBIT). The blended multiple obscures the pieces that move.
Watch two numbers, not twenty. First, whether Cigna Healthcare MCR retreats from 84.4% in Q2/Q3 FY2026. Second, the Evernorth adjusted operating income trajectory through the 2026 $6.9B floor toward the 2027 rebate-free launch.
Run the lost-Centene scenario at least once. One PBM client = 19% of group revenue. Contract runs to 2029-2030; the cliff is dated, the counterparty is stressed.
Regulatory overhang is dated, not surprising. CAA 2026 imposes 100% rebate pass-through on ERISA plans from August 2028 and bans list-price-linked PBM compensation in Part D from January 2028. The October 2025 rebate-free announcement got ahead of both. Risk is execution.
The single mistake to avoid: trading on consolidated revenue or GAAP net income — both swung on HCSC and VillageMD. Look at adjusted income from operations ($8.0B → $8.0B → $8.0B over 2023-2025, guided to $8.2B+ for 2026) and segment KPIs.